SINOVAC-BIOTECH
Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that its COVID-19 vaccine (CoronaVac) has been approved by the Brazilian Health Regulatory Agency (Anvisa) for emergency use in children from 3 to 5 years old on 13 July. These children will receive the same dose that is already applied to minors aged 6 to 17 years and adults and there is no restriction on the application for immunosuppressed children aged 3 to 5 years.
This authorization was given under comprehensive evaluations based on analysis results from all available data on the vaccine and its use in children. Analysis relied on information submitted by the Butantan Institute, with research data from Chile, where the vaccine is already used in this age group, research results on Covid-19 vaccination in Brazil, opinions from invited medical societies, real-life evidence, and published scientific literature data.
Participants in this evaluation activity were the Brazilian Society of Pediatrics (SBP), the Brazilian Society of Infectious Diseases (SBI), the Brazilian Society of Pneumology and Phthisiology (SBPT), the Brazilian Society of Immunizations (SBIm), and the Brazilian Association of Collective Health (Abrasco). To assist Anvisa in evaluating the vaccine, the experts from the above institutions had access to technical materials and research data on the vaccine.
CoronaVac has been authorized for emergency use for adults in Brazil since January 17, 2021. Following, the Anvisa authorized the extension of the use of the vaccine to children and adolescents 6 to 17 years of age on January 20, 2022.
As of July 14, 2022, CoronaVac is authorized for Emergency Use for minors in 14 countries and regions, including Chile, Colombia, Ecuador, Brazil, and the countries and regions in Asia and Africa.
About SIONVAC
Sinovac Biotech Ltd., (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.
SINOVAC’s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A and B, seasonal influenza, pneumococcal disease, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella, mumps, and poliomyelitis.
The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The Healive®, hepatitis A vaccine, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine commercialized in China in 2016. In 2022, SINOVAC’s Sabin-strain inactivated polio vaccine (sIPV) was prequalified by the WHO.
SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.
SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.
For more information, please see the Company’s website at www.sinovac.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220714005372/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pacsun Successfully Implements Manhattan Active® Point of Sale, Unifying Commerce and Cutting Checkout Times19.11.2025 09:00:00 CET | Press release
Manhattan Associates Inc. (NASDAQ: MANH) today announced that Pacsun, a leading youth fashion retailer, has successfully deployed Manhattan Active® Point of Sale (POS), a cloud-native in-store sales and service solution that empowers associates to merge digital convenience with personalised retailing. Following a five-month project start to pilot phase, Pacsun rolled out Manhattan's POS solution across 300 plus stores in just eight weeks. Mobile checkout capabilities eased long in-store lines, while unified inventory management, powered by RFID integration, supported seamless fulfilment across Instagram, Amazon, TikTok and Pacsun’s own channels. During peak holiday season, Pacsun achieved record breaking revenue and streamlined operations, with 40% of online orders being fulfilled via stores, optimising inventory proximity, labour capacity and shipping costs that reduced logistics expenses by 25%. Stores are now critical drivers of retail differentiation, with industry research showing
Frontgrade Gaisler and DELTATEC Enable Advanced Space Computing Across Multiple Missions19.11.2025 09:00:00 CET | Press release
Frontgrade™ Gaisler Technologies a leading provider of high-reliability electronic solutions for space and national security missions, and DELTATEC,a very high-level design house specialized in advanced technologies are pleased to celebrate their successful collaboration in delivering high-performance computing solutions for space applications, with the GR712RC dual-core microprocessor at the heart of several flight-proven systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251119011567/en/ The GR712RC, developed by Frontgrade Gaisler and based on the fault-tolerant LEON3FT architecture, has been integrated into multiple Data Handling System (DHS) units designed by DELTATEC. These include one Payload Data Handling Unit (PDHU) and two On-Board Computers (OBCs) currently operating aboard ESA’s eSAIL mission, launched into Low Earth Orbit (LEO) in September 2020. Moreover, DELTATEC recently delivered the Flight Model of the
AGC Biologics and Repair Biotechnologies Partner on Novel mRNA Therapeutic to Combat the Leading Cause of Human Mortality19.11.2025 09:00:00 CET | Press release
Partnership leverages AGC Biologics’ cost-effective and dependable cGMP mRNA and LNP capabilities AGC Biologics today announced it is partnering with Repair Biotechnologies to tackle one of the world's most persistent health challenges and cause of mortality. The collaboration will focus on developing and manufacturing a novel mRNA therapy to rapidly stabilize and reduce the size of atherosclerotic plaques in major blood vessels. Rupture of unstable plaque and subsequent heart attack or stroke is the leading cause of death, accounting for 27% of all human mortality. “Developing a novel mRNA therapeutic as a part of the vital goal of curing atherosclerotic cardiovascular disease is a complex task, and robust manufacturing is critical to our progress,” said Reason, CEO and co-founder, Repair Biotechnologies. “We chose AGC Biologics because they have mastered the entire production chain for therapeutics of this class, eliminating critical risks and delays to provide a fast and reliable pa
Wasabi Introduces High-Performance Class and Expands into Silicon Valley to Take on AI’s Rising Data Storage Costs19.11.2025 09:00:00 CET | Press release
Wasabi Fire and AI-ready San Jose region give organizations a powerful alternative to hyperscalers, combining speed, simplicity, and predictable pricing for AI workloads Wasabi Technologies, the Hot Cloud Storage company, expanded further into artificial intelligence with the unveiling of Wasabi Fire, a high-performance storage class that supports AI workloads, available beginning in early 2026. Wasabi has also opened a new storage region in San Jose, Calif., as part of its relationship with IBM Cloud. The milestones reinforce Wasabi’s push to expand its role in AI infrastructure as demand for scalable, high-performance and cost-efficient cloud storage accelerates. “Object storage is the backbone of AI, but customers shouldn’t have to choose between speed and cost,” said David Friend, co-founder and CEO of Wasabi Technologies. “With Wasabi Fire, we’re delivering NVMe performance at disruptive prices, allowing organizations to cost-effectively store the critical data needed to train AI.
Aqara's Next-Generation Radiator Thermostat Delivers Smarter, Greener Heating to European Homes19.11.2025 09:00:00 CET | Press release
Aqara, a global leader and pioneer in IoT, today announces the availability of its Radiator Thermostat W600, first unveiled at IFA 2025. Boasting smart features like convenient temperature control, automated climate regulation, and seamless interoperability across Matter ecosystems via Thread/Zigbee protocol, the W600 transforms traditional radiators into intelligent, energy-efficient heating systems that not only enhance comfort but also help reduce energy bills. Designed for sustainable living, the Radiator Thermostat W600 delivers energy savings by minimizing heating in unoccupied areas. Instead of heating the whole home, users can schedule temperature adjustments for individual rooms, with up to 7 time periods per day, aligning with daily routines. Furthermore, these thermostatic radiator valves (TRV) can regulate indoor temperature based on environmental and behavioral triggers like room occupancy and geofencing, allowing for a heating system that adapts to real-time usage and occ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom